In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended remissions and protection against PsA relative to other biologics.

Greg Gumbel's former CBS Sports colleagues are paying tribute to him Sunday. Today is a bittersweet day for the CBS Sports ...

Three months after Bristol Myers Squibb revealed the success of two phase 3 trials of its oral targeted therapy Sotyktu in ...

FINE SLAMS WEIL — State Sen. RANDY FINE (R-Melbourne) slammed his Democratic congressional opponent, JOSH WEIL, after a ...

"The clinical promise of pocenbrodib, our potential best-in-class CBP/p300 inhibitor, lies not only in its remarkable efficacy in resistant prostate cancer models, but also in our sophisticated ...

Jyong Biotech Ltd. (Revived IPO) (MENS) expects to raise $22 million in an IPO on Wednesday, April 2nd, IPO Scoop reports. The company plans to issue 2,700,000 shares at $7.50-$8.50 per share. The ...

HSBC lowered its target price for Sun Pharmaceuticals to ₹2,000, maintaining a ’buy’ rating. The revision reflects clinical trial delays and increased R&D investments, but the firm remains optimistic ...

So as way of background, EZH2 is an epigenetic enzyme that's overexpressed in castrate-resistant prostate cancer, and it's ...

To further raise awareness, MADD Canada has launched a new Public Service Announcement (PSA) titled Heroes, which targets young men and challenges the dangerous misconception that they can drive after ...